脑脊液tau与β-淀粉样蛋白预测尸检路易体病中的脑α-突触核蛋白病理
研究纳入尸检确诊的路易体病(LBD)24例、阿尔茨海默病(AD)23例和认知正常对照36例,比较生前脑脊液生物标志物与死后全脑病理评分。结果显示,LBD合并中/重度AD共病理者脑脊液总tau较高、Aβ1-42较低;脑脊液总tau/Aβ1-42比值对识别该组特异性100%、敏感性90%。作者认为这些标志物可能识别易发生皮质α-突触核蛋白病理的LBD患者。
要点
- LBD合并中/重度AD共病理者脑脊液总tau较无/轻度AD共病理者高27.0±8.6 pg/mL。
- LBD合并中/重度AD共病理者脑脊液Aβ1-42较无/轻度AD共病理者低84.0±22.9 g/mL。
- 脑脊液总tau/Aβ1-42比值识别LBD合并中/重度AD共病理的敏感性90%、特异性100%。
核心结论
- 较高的生前脑脊液总tau/Aβ1-42比值和较低的Aβ1-42水平可预测脑内AD病理和α-突触核蛋白病理加重。
- 这些生物标志物可能识别易发生皮质α-突触核蛋白病理、可能受益于针对α-突触核蛋白和AD的疾病修饰治疗的LBD患者。
研究设计与样本
- 研究纳入尸检确诊的LBD患者24例、尸检确诊的AD患者23例和认知正常对照36例。
- 在LBD中,神经病理标准定义路易体α-突触核蛋白(SYN)分期,并分为中/重度AD共病理组(SYN+AD=10)和无/轻度AD共病理组(SYN-AD=14)。
- 对tau、β-淀粉样蛋白(Aβ)和SYN病理的序数评分在7个皮质区域取平均,获得每种病理的全脑评分。
- 比较LBD组与对照组之间脑脊液总tau、苏氨酸181磷酸化tau和Aβ1-42水平,并用线性回归分析其与LBD全脑病理评分的相关性。
- 用受试者工作特征曲线检验脑脊液标志物对LBD死后分类为SYN+AD vs SYN-AD或新皮质 vs 脑干/边缘系统SYN分期的诊断准确性。
主要发现
- SYN+AD组脑脊液总tau较SYN-AD组高27.0±8.6 pg/mL,Aβ1-42较SYN-AD组低84.0±22.9 g/mL(两者p<0.01)。
- 全脑tau和斑块评分增加与脑脊液总tau升高(R2=0.15-0.16,p<0.05,两者)和Aβ1-42降低(R2=0.43-0.49,p<0.001,两者)相关。
- 全脑SYN评分增加与脑脊液Aβ1-42降低(R2=0.31,p<0.001)和总tau/Aβ1-42比值升高(R2=0.27,p=0.01)相关。
- 脑脊液总tau/Aβ1-42比值对SYN+AD的敏感性为90%、特异性为100%。
- 脑脊液Aβ1-42对新皮质SYN分期的敏感性为82%、特异性为77%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To test the association of antemortem CSF biomarkers with postmortem pathology in Lewy body disorders (LBD). METHODS: Patients with autopsy-confirmed LBD (n = 24) and autopsy-confirmed Alzheimer disease (AD) (n = 23) and cognitively normal (n = 36) controls were studied. In LBD, neuropathologic criteria defined Lewy body α-synuclein (SYN) stages with medium/high AD copathology (SYN + AD = 10) and low/no AD copathology (SYN - AD = 14). Ordinal pathology scores for tau, β-amyloid (Aβ), and SYN pathology were averaged across 7 cortical regions to obtain a global cerebral score for each pathology. CSF total tau (t-tau), phosphorylated tau at threonine181, and Aβ1-42 levels were compared between LBD and control groups and correlated with global cerebral pathology scores in LBD with linear regression. Diagnostic accuracy for postmortem categorization of LBD into SYN + AD vs SYN - AD or neocortical vs brainstem/limbic SYN stage was tested with receiver operating curves. RESULTS: SYN + AD had higher CSF t-tau (mean difference 27.0 ± 8.6 pg/mL) and lower Aβ1-42 (mean difference -84.0 ± 22.9 g/mL) compared to SYN - AD (p < 0.01, both). Increasing global cerebral tau and plaque scores were associated with higher CSF t-tau (R2 = 0.15-0.16, p < 0.05, both) and lower Aβ1-42 (R2 = 0.43-0.49, p < 0.001, both), while increasing cerebral SYN scores were associated with lower CSF Aβ1-42 (R2 = 0.31, p < 0.001) and higher CSF t-tau/Aβ1-42 ratio (R2 = 0.27, p = 0.01). CSF t-tau/Aβ1-42 ratio had 100% specificity and 90% sensitivity for SYN + AD, and CSF Aβ1-42 had 77% specificity and 82% sensitivity for neocortical SYN stage. CONCLUSIONS: Higher antemortem CSF t-tau/Aβ1-42 and lower Aβ1-42 levels are predictive of increasing cerebral AD and SYN pathology. These biomarkers may identify patients with LBD vulnerable to cortical SYN pathology who may benefit from both SYN and AD-targeted disease-modifying therapies.
引用
- Irwin DJ, Xie SX, Coughlin D, et al. CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. Neurology. 2018. PMID: 29467305. doi:10.1212/WNL.0000000000005166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。